Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FOLLISTIM AQ vs A.P.L.
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on granulosa cells in the ovary, stimulating follicular growth and maturation via activation of adenylyl cyclase and increased c AMP production.
A. P. L. (Chorionic Gonadotropin) acts as a luteinizing hormone (LH) agonist, binding to LH receptors in the gonads to stimulate testosterone production in males and ovulation in females.
Ovulation induction in anovulatory women,Development of multiple follicles in assisted reproductive technologies (ART),Controlled ovarian hyperstimulation for in vitro fertilization (IVF),Hypogonadotropic hypogonadism (off-label)
Induction of ovulation in anovulatory infertile women,Treatment of hypogonadism and cryptorchidism in males,Off-label: Assisted reproductive technology (ART) protocols
75 to 300 IU subcutaneously once daily for 8 to 14 days, adjusted based on follicular response; maximum daily dose 450 IU and total duration not exceeding 14 days per cycle.
500-1000 mg every 4-6 hours, not to exceed 3000 mg/day in adults.
Terminal elimination half-life approximately 24-36 hours (subcutaneous route); clinical context supports daily dosing due to sustained follicular stimulation.
Terminal elimination half-life: 2.5–3.5 hours (elimination phase); clinical context: requires repeated dosing for sustained effect.
Metabolized via hepatic and renal pathways; exact enzymes not specified.
Primarily via glucuronidation (60%) and sulfation (35%) in the liver, with a minor portion (5%) via CYP2E1 oxidation to the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI), which is normally detoxified by glutathione.
Primarily renal (90%), with intact follitropin alfa/beta and metabolites excreted in urine; biliary/fecal excretion minimal (<10%).
Renal: 10% unchanged; hepatic metabolism to inactive metabolites excreted in urine and feces (90% combined).
Approximately 60-70% bound to plasma proteins, primarily albumin.
80–90% bound to sex hormone-binding globulin (SHBG) and albumin.
Approximately 0.5-1.0 L/kg, indicating distribution primarily into extracellular fluid; limited tissue binding.
0.5–0.9 L/kg, indicating moderate tissue distribution (primarily gonads and liver).
Subcutaneous injection: approximately 70% (relative to IV); intramuscular injection: approximately 60-70%.
IM: 100%; Subcutaneous: ~80% (relative to IM); Oral: <5% (not clinically used).
No formal guidelines; use with caution in moderate to severe renal impairment (e GFR <30 m L/min/1.73 m²) due to limited data; consider lower starting doses based on clinical response.
No specific adjustment required for mild to moderate renal impairment. In severe renal impairment (Cr Cl < 10 m L/min), extend dosing interval to every 8 hours.
No formal guidelines; use with caution in Child-Pugh class B or C cirrhosis due to potential altered metabolism; monitor response and consider dose reduction.
Caution in severe hepatic impairment; consider dose reduction or extended interval. Avoid use in active liver disease.
Not FDA-approved for pediatric use; limited off-label data for anovulatory disorders: start at 75 IU subcutaneously once daily, adjusted per response, based on body weight (1.5-3 IU/kg/day) with careful monitoring.
Weight-based: 10-15 mg/kg every 4-6 hours, not to exceed 5 doses per day or 75 mg/kg/day.
Not indicated for geriatric use in fertility; no specific dosing recommendations; consider increased risk of adverse events if used off-label; monitor closely.
No specific dose adjustment, but consider renal and hepatic function and avoid exceeding 3000 mg/day.
None.
No black box warning.
Ovarian hyperstimulation syndrome (OHSS),Ovarian torsion,Multiple pregnancies,Pulmonary embolism,Ovarian enlargement,Ectopic pregnancy,Congenital malformations
May cause fluid retention, ovarian hyperstimulation syndrome (OHSS) in females,Increased risk of thromboembolic events,Precocious puberty in males,Not for use in prepubertal children unless for cryptorchidism
Hypersensitivity to FSH or excipients,Primary ovarian failure,Ovarian cyst or enlargement of unknown origin,Gynecological cancers (ovarian, breast, uterine),Pregnancy,Uncontrolled thyroid or adrenal dysfunction,Presence of non-gonadal endocrine disorders (e.g., pituitary tumor)
Hypersensitivity to chorionic gonadotropin or any component,Precocious puberty (in males),Prostatic carcinoma or other androgen-dependent neoplasms,Ovarian cyst or enlargement not due to polycystic ovary syndrome
No significant food interactions. Maintain a healthy diet; no specific restrictions.
No known food interactions. Avoid alcohol during treatment.
Follistim Aq (follitropin beta) is classified as Pregnancy Category X. It is contraindicated in pregnant women due to the risk of ovarian hyperstimulation syndrome and potential fetal harm. First trimester: No adequate human data, but animal studies show embryotoxicity. Second and third trimesters: Not indicated for use; may cause fetal harm if inadvertently administered during early pregnancy.
A. P. L. (chorionic gonadotropin) is not expected to increase the risk of congenital anomalies when used in early pregnancy. However, use in the first trimester is generally avoided unless indicated for specific conditions. Data are limited; no increased fetal risk reported in inadvertent exposures. Second and third trimester use is not associated with teratogenicity but may increase risk of multiple gestation (if used for ovulation induction).
Excretion into human milk is unknown. Due to the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment. M/P ratio is not available.
Chorionic gonadotropin is not detected in breast milk following maternal administration. M/P ratio not established. Considered compatible with breastfeeding; no adverse effects on infant reported. Use with caution if high doses are administered.
Not applicable; Follistim Aq is contraindicated during pregnancy. No pharmacokinetic data are available for pregnant women; thus, no dose adjustments are recommended as the drug should not be used in pregnancy.
No pharmacokinetic studies in pregnancy. Dose adjustments are not typically required during pregnancy for standard indications. For ovulation induction, dosing is based on follicular development. In first trimester for luteal support, standard doses are used. No evidence of altered clearance or need for dose changes due to pregnancy.
Administer subcutaneously; rotate injection sites to avoid lipodystrophy. Do not administer if solution contains particles or discoloration. Use the lowest effective dose to minimize risk of ovarian hyperstimulation syndrome (OHSS). Monitor estradiol levels and ultrasound for follicular development. Discontinue if pregnancy occurs. Store in refrigerator at 2-8°C; do not freeze. Protect from light.
A. P. L. (chorionic gonadotropin) is used to trigger ovulation in assisted reproductive technology. Administer when follicles are mature (≥18 mm). Risk of ovarian hyperstimulation syndrome (OHSS) increases with higher doses. Monitor for abdominal pain, distension, and weight gain. Use caution in patients with prior thromboembolism.
Inject exactly as prescribed; do not change dose without consulting your doctor.,Rotate injection sites (abdomen, thigh) to prevent lumps or skin reactions.,Report severe pelvic pain, nausea, vomiting, or rapid weight gain (signs of OHSS) immediately.,Avoid pregnancy during treatment; use barrier contraception until advised by your doctor.,Do not shake the cartridge; gently swirl to mix.,Store in the refrigerator; do not freeze. If unrefrigerated, use within 28 days at room temperature (≤25°C).,Discard any unused solution after the course of treatment.
This medication is given as an injection exactly as prescribed to trigger ovulation.,A single dose is usually sufficient; follow your doctor's timing instructions closely.,Common side effects include headache, fatigue, and injection site reactions.,Seek immediate medical help if you experience severe pelvic pain, nausea, vomiting, or sudden weight gain (signs of OHSS).,Report symptoms of blood clots: leg pain, chest pain, or shortness of breath.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FOLLISTIM AQ vs A.P.L., answered by our medical review team.
FOLLISTIM AQ is a Gonadotropin that works by Recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on granulosa cells in the ovary, stimulating follicular growth and maturation via activation of adenylyl cyclase and increased c AMP production.. A.P.L. is a Gonadotropin that works by A. P. L. (Chorionic Gonadotropin) acts as a luteinizing hormone (LH) agonist, binding to LH receptors in the gonads to stimulate testosterone production in males and ovulation in females.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FOLLISTIM AQ and A.P.L. depend on the specific clinical indication. These are both Gonadotropin agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FOLLISTIM AQ is: 75 to 300 IU subcutaneously once daily for 8 to 14 days, adjusted based on follicular response; maximum daily dose 450 IU and total duration not exceeding 14 days per cycle.. The standard adult dose of A.P.L. is: 500-1000 mg every 4-6 hours, not to exceed 3000 mg/day in adults.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FOLLISTIM AQ and A.P.L. in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FOLLISTIM AQ is classified as Category C. Follistim Aq (follitropin beta) is classified as Pregnancy Category X. It is contraindicated in pregnant women due to the risk of ovarian hyperstimulation syndrome and potential fe. A.P.L. is classified as Category C. A.P.L. (chorionic gonadotropin) is not expected to increase the risk of congenital anomalies when used in early pregnancy. However, use in the first trimester is generally avoided . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.